After two years in the market’s penalty box, biotech is showing signs of life again — especially in the small-cap and mid-cap segments. While big names like Amgen and Gilead remain stable plays, the real opportunity may lie in earlier-stage firms with breakthrough therapies and cleaned-up balance sheets.

‍

The iShares Biotechnology ETF (IBB) is up nearly 20% year-to-date, its best stretch since late 2020. That shift isn’t just about macro rotation — it’s being driven by clear signals from the FDA, improving funding conditions, and a renewed appetite for M&A.

‍

Regulatory Green Lights Are Back

‍

From 2022 through early 2024, the FDA took a noticeably conservative stance, and approval timelines became longer and less predictable. That began to shift in mid-2024. So far this year, the agency has already approved 22 novel drugs, including several in oncology and rare disease — both high-value targets for small developers.

‍

Companies like Karuna Therapeutics and Day One Biopharma, once considered too speculative, are now viewed as potential takeover targets following clean Phase 3 readouts. Institutional investors, including biotech-focused hedge funds, have started rotating capital back into these names — often before approval, not after.

‍

Big Pharma Needs Pipelines, Not Just Profits

‍

Large-cap pharmaceutical companies are facing an uncomfortable reality: $200 billion in drug revenue is set to go off-patent by 2030, creating a pipeline pressure not seen since the early 2010s. That has triggered a renewed M&A cycle, with Pfizer, Merck, and Bristol Myers all expressing interest in early-stage biotech assets that can be scaled post-approval.

‍

Unlike the megamergers of the past, today’s deals are more targeted and scientific, focused on companies with validated assets, fast-track designations, and clearly defined patient populations. For small biotech firms with orphan drug exclusivity or biomarker-based treatments, this is the moment they’ve been building toward.

‍

Retail Investors Are Returning — Cautiously

‍

Retail traders largely exited the sector after the 2021 bubble burst. But platforms like XBI and ARKG, which track early-stage and genomic medicine stocks, have seen a steady uptick in flows over the past 90 days. Momentum is coming not from hype, but from clinical success and real revenue potential.

‍

The difference now is discipline. Investors are favoring firms with low cash burn, milestone payments from partners, or existing commercial revenue. Companies like Verona Pharma and Argenx are now drawing more attention than speculative gene-editing names that once dominated headlines.

‍

Biotech in 2025 Feels More Like 2013 Than 2021

‍

Ten years ago, biotech began a multi-year bull run as new platforms like immunotherapy and CAR-T took hold. What followed was a surge in innovation — and returns. The current setup shares some key features: low expectations, innovation in oncology and neurology, and a hungry group of acquirers.

‍

The sector still carries risk, especially with interest rates elevated and investor memory fresh from recent drawdowns. But with volatility comes pricing inefficiency, and that’s exactly where savvy investors thrive.

‍

If history’s any guide, the quiet rally happening in biotech right now might be the start of something much louder.

‍

‍

Disclaimer

We are not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authorities. Further, our owners, employees, agents are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authorities.

‍

The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

‍

The content on any of our websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors.

‍

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.

‍

Disclaimer: Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and our partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing herein constitutes a recommendation respecting the particular security illustrated.

‍